CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,141,767 | -61.6% | 104,271 | -69.4% | 0.01% | -62.5% |
| Q1 2023 | $2,970,363 | +63.3% | 340,638 | +17.4% | 0.02% | +60.0% |
| Q4 2022 | $1,819,391 | +96.1% | 290,174 | +9.5% | 0.01% | +66.7% |
| Q3 2022 | $928,000 | +115.8% | 265,062 | +81.7% | 0.01% | +100.0% |
| Q2 2022 | $430,000 | +105.7% | 145,913 | +117.1% | 0.00% | +200.0% |
| Q1 2022 | $209,000 | -59.0% | 67,221 | -24.3% | 0.00% | -66.7% |
| Q4 2020 | $510,000 | -61.8% | 88,837 | -51.8% | 0.00% | -66.7% |
| Q3 2020 | $1,335,000 | +56.0% | 184,394 | -24.8% | 0.01% | +50.0% |
| Q2 2020 | $856,000 | +394.8% | 245,330 | +110.4% | 0.01% | +200.0% |
| Q1 2020 | $173,000 | +220.4% | 116,575 | +321.6% | 0.00% | – |
| Q4 2019 | $54,000 | – | 27,650 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |